Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.22
MACK's Cash to Debt is ranked lower than
92% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 41.89 vs. MACK: 0.22 )
Ranked among companies with meaningful Cash to Debt only.
MACK' s Cash to Debt Range Over the Past 10 Years
Min: 0.22  Med: 1.89 Max: No Debt
Current: 0.22
Equity to Asset -1.92
MACK's Equity to Asset is ranked lower than
98% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MACK: -1.92 )
Ranked among companies with meaningful Equity to Asset only.
MACK' s Equity to Asset Range Over the Past 10 Years
Min: -4.85  Med: -0.9 Max: 0.24
Current: -1.92
-4.85
0.24
F-Score: 3
Z-Score: -12.83
M-Score: 5.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -121.16
MACK's Operating margin (%) is ranked lower than
54% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. MACK: -121.16 )
Ranked among companies with meaningful Operating margin (%) only.
MACK' s Operating margin (%) Range Over the Past 10 Years
Min: -2220.11  Med: -236.36 Max: -64.48
Current: -121.16
-2220.11
-64.48
Net-margin (%) -159.99
MACK's Net-margin (%) is ranked lower than
57% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. MACK: -159.99 )
Ranked among companies with meaningful Net-margin (%) only.
MACK' s Net-margin (%) Range Over the Past 10 Years
Min: -2284.59  Med: -231.54 Max: -81.06
Current: -159.99
-2284.59
-81.06
ROA (%) -104.59
MACK's ROA (%) is ranked lower than
86% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: -30.04 vs. MACK: -104.59 )
Ranked among companies with meaningful ROA (%) only.
MACK' s ROA (%) Range Over the Past 10 Years
Min: -110.9  Med: -75.22 Max: -47.47
Current: -104.59
-110.9
-47.47
ROC (Joel Greenblatt) (%) -629.10
MACK's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. MACK: -629.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MACK' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1458.87  Med: -732.8 Max: -468.88
Current: -629.1
-1458.87
-468.88
Revenue Growth (3Y)(%) 6.10
MACK's Revenue Growth (3Y)(%) is ranked higher than
52% of the 471 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. MACK: 6.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MACK' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -33.65 Max: 6.1
Current: 6.1
0
6.1
EBITDA Growth (3Y)(%) -2.40
MACK's EBITDA Growth (3Y)(%) is ranked lower than
54% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. MACK: -2.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MACK' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -44 Max: -2.4
Current: -2.4
EPS Growth (3Y)(%) 1.30
MACK's EPS Growth (3Y)(%) is ranked higher than
55% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. MACK: 1.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MACK' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -45.5 Max: 1.3
Current: 1.3
0
1.3
GuruFocus has detected 6 Warning Signs with Merrimack Pharmaceuticals Inc $MACK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MACK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MACK Guru Trades in Q4 2015

Murray Stahl 25,000 sh (unchged)
» More
Q1 2016

MACK Guru Trades in Q1 2016

Paul Tudor Jones 17,800 sh (New)
Jim Simons 636,613 sh (New)
Murray Stahl 25,000 sh (unchged)
» More
Q2 2016

MACK Guru Trades in Q2 2016

Jim Simons 744,813 sh (+17.00%)
Murray Stahl 25,000 sh (unchged)
Paul Tudor Jones 11,400 sh (-35.96%)
» More
Q3 2016

MACK Guru Trades in Q3 2016

Murray Stahl 25,000 sh (unchged)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MACK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:OMER, NAS:PDLI, NAS:MRUS, NAS:MYOK, NAS:XBIT, NAS:ATRA, NAS:FOMX, NAS:SPPI, NAS:NERV, NAS:MCRB, NAS:BSTC, NAS:LJPC, NAS:NVAX, NAS:AKBA, NAS:CRIS, NAS:NSTG, NAS:CCXI, NAS:TLGT, NAS:CTMX, OTCPK:ZLDPF » details
Traded in other countries:MP6.Germany,
Merrimack Pharmaceuticals Inc is engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer.

Merrimack Pharmaceuticals Inc was incorporated in 1993 and reincorporated in the state of Delaware in October 2010. The Company is engaged in discovering, developing and preparing to commercialize medicines consisting of novel therapeutics paired with companion diagnostics for the treatment of cancer. It faces competition from specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. The Company is subject to rules and regulations from the federal, state and local authorities.

Ratios

vs
industry
vs
history
P/S 3.46
MACK's P/S is ranked higher than
77% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 10.85 vs. MACK: 3.46 )
Ranked among companies with meaningful P/S only.
MACK' s P/S Range Over the Past 10 Years
Min: 1.78  Med: 8.98 Max: 16.67
Current: 3.46
1.78
16.67
Current Ratio 1.02
MACK's Current Ratio is ranked lower than
87% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. MACK: 1.02 )
Ranked among companies with meaningful Current Ratio only.
MACK' s Current Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.9 Max: 4.51
Current: 1.02
0.69
4.51
Quick Ratio 0.85
MACK's Quick Ratio is ranked lower than
86% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. MACK: 0.85 )
Ranked among companies with meaningful Quick Ratio only.
MACK' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.88 Max: 4.51
Current: 0.85
0.69
4.51
Days Inventory 780.17
MACK's Days Inventory is ranked lower than
98% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 127.64 vs. MACK: 780.17 )
Ranked among companies with meaningful Days Inventory only.
MACK' s Days Inventory Range Over the Past 10 Years
Min: 780.17  Med: 14746.79 Max: 14746.79
Current: 780.17
780.17
14746.79
Days Sales Outstanding 77.47
MACK's Days Sales Outstanding is ranked lower than
61% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 61.83 vs. MACK: 77.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
MACK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 11.77  Med: 67.32 Max: 300.77
Current: 77.47
11.77
300.77
Days Payable 813.85
MACK's Days Payable is ranked higher than
98% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 58.15 vs. MACK: 813.85 )
Ranked among companies with meaningful Days Payable only.
MACK' s Days Payable Range Over the Past 10 Years
Min: 9.02  Med: 22 Max: 40062.72
Current: 813.85
9.02
40062.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -6.50
MACK's 3-Year Average Share Buyback Ratio is ranked higher than
65% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. MACK: -6.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MACK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -111.1  Med: -58.5 Max: 0
Current: -6.5
-111.1
0

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.39
MACK's Price/Median PS Value is ranked higher than
85% of the 593 Companies
in the Global Biotechnology industry.

( Industry Median: 0.94 vs. MACK: 0.39 )
Ranked among companies with meaningful Price/Median PS Value only.
MACK' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.2  Med: 1.09 Max: 1.5
Current: 0.39
0.2
1.5
Earnings Yield (Greenblatt) (%) -22.51
MACK's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 924 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. MACK: -22.51 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MACK' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -23.21  Med: 0 Max: 0
Current: -22.51
-23.21
0

More Statistics

Revenue (TTM) (Mil) $104.5
EPS (TTM) $ -1.38
Beta2.39
Short Percentage of Float41.19%
52-Week Range $2.85 - 9.02
Shares Outstanding (Mil)129.62

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 183 202 316
EPS ($) -0.91 -0.93 -0.42
EPS w/o NRI ($) -0.91 -0.93 -0.42
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MACK

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Starbucks Corp, KD Supply Holdings Inc, Capital One Financial Corp, Merr Dec 14 2014 

More From Other Websites
MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Jan 20 2017
Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO Jan 18 2017
Merrimack (MACK) Goes Uphill: Is a Turnaround Likely? Jan 17 2017
DryShips, Alcobra Sink into Tuesday’s 52-Week Low Club Jan 17 2017
Merrimack Pharmaceuticals Prospects for the New MACK and Review Jan 17 2017
Latest Reports on Diffusion and Merrimack as Drug Stocks are Hit by President Trump's Comments Jan 12 2017
Macy’s, Teva Join Wednesday’s 52-Week Low Club Jan 11 2017
Is the Options Market Predicting a Spike in Merrimack (MACK) Stock? Jan 11 2017
DryShips, Merrimack Pharma Stuck in Tuesday’s 52-Week Low Club Jan 10 2017
Merrimack Pharmaceuticals Inc (MACK) Cancer Drugs Sold To Ipsen Jan 10 2017
Company News for January 10, 2017 Jan 10 2017
Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B Jan 09 2017
So the Nasdaq Is At a Historical High but the Dow Is Going Opposite Direction Jan 09 2017
Merrimack Pharma to Sell Cancer Drugs for $1B Jan 09 2017
Merrimack Sells Pancreatic Cancer Drug to Ipsen for $1 Billion Jan 09 2017
Biotech Stocks Surge Monday Amid Flurry of Deal Activity Jan 09 2017
Monday’s 4 Biggest Biopharma Movers Jan 09 2017
Merrimack Pharmaceuticals' stock soars on heavy volume after drug sale deal Jan 09 2017
Stock Futures Mostly Lower as Crude Oil Slides Below $53 Jan 09 2017
France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal Jan 09 2017
Ipsen to buy some Merrimack assets for about $1 billion Jan 08 2017
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals Jan 08 2017
Exclusive: U.S. drugmaker Merrimack nears deal with France's Ipsen - sources Jan 08 2017
Merrimack Stops the Phase 2 HERMIONE Trial of MM-302 in HER2-Positive Metastatic Breast Cancer... Dec 21 2016
Merrimack Reports Third Quarter 2016 Financial Results Nov 09 2016
Merrimack Announces Timing of Third Quarter 2016 Investor Conference Call Nov 02 2016
Merrimack Announces Acceptance for Review of ANDA filed by Actavis for Generic Doxorubicin... Oct 31 2016
Final Results of NAPOLI-1 Study Confirm Overall Survival and Progression-Free Survival Benefit for... Oct 11 2016
Merrimack Announces Major Corporate Restructuring Oct 03 2016
Merrimack Reports Second Quarter 2016 Financial Results Aug 04 2016
Merrimack Announces ONIVYDE® Regimen Receives Positive CHMP Opinion in European Union Jul 25 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer Jul 06 2016
NAPOLI-1 Data Demonstrates ONIVYDE® Regimen Maintains Quality of Life While Improving Overall... Jun 30 2016
Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in... Jun 21 2016
Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on... Jun 21 2016
Merrimack and Baxalta Announce Initiation of Phase 1 Study of MM-151 in Combination with the... May 19 2016
Merrimack to Present on Extensive Oncology Pipeline at the 2016 American Society of Clinical... May 18 2016
Merrimack Presents Expanded Analysis from Seribantumab (MM-121) Phase 2 Breast Cancer Study at the... May 17 2016
Merrimack Reports First Quarter 2016 Financial Results May 02 2016
Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual... Apr 21 2016
Merrimack Announces Timing of First Quarter 2016 Investor Conference Call Apr 20 2016
Leica Biosystems and Merrimack Pharmaceuticals to Collaborate on Development of a Heregulin... Apr 14 2016
US STOCKS-Bed, Bath & Beyond, Merrimack Pharma surge in premarket Sep 24 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)